The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Predictors of early relapse in transplant-eligible MM patients
Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the integrative analysis of baseline prognostic features and achievement of measurable residual disease (MRD) negativity in an attempt to identify the main predictors of early relapse in transplant-eligible multiple myeloma (MM) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
